Fig. 1 · Structure

Documents & Downloads

Echinacoside

Cat. No. A12039 CAS 82854-37-3
Echinacoside was shown to promote proliferation of intestinal epithelial cells by increasing TGF-β1 expression.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Echinacoside Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of Echinacoside from 3 published references. In vitro models include human umbilical vein endothelial cells (HUVECs).

Echinacoside In Vitro Studies

In human umbilical vein endothelial cells, Echinacoside inhibited NF-κB and MAPK signaling pathways compared with the LPS group; these effects were reversed upon SIRT1 siRNA treatment. After PAO1 incubation with 250 nM Echinacoside for 6 h, 11.28 ± 9.68% of bacterial cells grew into aggregates larger than 1000 μm3. In untreated cells, aggregates larger than 1000 μm3 composed 43.61 ± 7.94% of total biovolume. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Signaling pathway inhibition in endothelial cells

Cell-based study · Human umbilical vein endothelial cells (HUVECs) [1]

In human umbilical vein endothelial cells, Echinacoside inhibited NF-κB and MAPK signaling pathways compared with the LPS group. The inhibitory effects were reversed upon SIRT1 siRNA treatment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Protein levels of Pho-p65, p65, Pho-IκB, IκB, Pho-ERK1/2, ERK1/2, Pho-JNK, JNK, Pho-p38, and p38 were detected by Western blottingReported result The inhibition of NF-κB and MAPK signaling pathways was observed with the reduction of the echinacoside concentration gradient compared to the LPS group; the inhibitory effects of echinacoside on the NF-κB and MAPK signaling pathways were reversed upon SIRT1 siRNA treatment.[1]

Literature-Reported Treatment Conditions

Co-treatment
Other interventions in this design: LPS. Compound effect isolated by the comparison: compared to the LPS group.
Reported limits
Not stated in the sentences used: dose, route, schedule, vehicle.
Methods and source locations

Compound reported in the paper: Echinacoside

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Materials and Methods > 2.9. Cell Culture (S33); 3. Results > 3.3. Echinacoside Mitigated the Pathological Activation of Endothelial Cells by Inhibiting LPS-Activited the NF-κB and MAPK Signaling Pathways (S100, S101); 3. Results > 3.5. SIRT1 Mediated the Protective Effects of Echinacoside against LPS-Induced Pathological Activation of Endothelial Cells (S114); Figure 3 legend (S168)

Protein levels of Pho-p65, p65, Pho-IκB, IκB, Pho-ERK1/2, ERK1/2, Pho-JNK, JNK, Pho-p38, and p38 were detected by Western blotting: Protein levels of Pho-p65, p65, Pho-IκB, IκB, Pho-ERK1/2, ERK1/2, Pho-JNK, JNK, Pho-p38, and p38 were detected by Western blotting; comparator: LPS group — 3. Results > 3.3. Echinacoside Mitigated the Pathological Activation of Endothelial Cells by Inhibiting LPS-Activited the NF-κB and MAPK Signaling Pathways (S101); 3. Results > 3.5. SIRT1 Mediated the Protective Effects of Echinacoside against LPS-Induced Pathological Activation of Endothelial Cells (S114); Figure 3 legend (S168)

Bacterial aggregation following treatment

Cell-based study · 1 × 105 CFU/mL PAO1 [2]

PAO1 was incubated with 250 nM Echinacoside for 6 h. Only 11.28 ± 9.68% of bacterial cells grew into aggregates larger than 1000 μm3. In untreated cells, aggregates larger than 1000 μm3 composed 43.61 ± 7.94% of total biovolume.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
aggregates larger than 1000 μm3aggregate biovolume proportion 1 × 105 CFU/mL PAO1, 250 nM echinacoside, after 6 h: 11.28 ± 9.68%[2]

Literature-Reported Treatment Conditions

Treatment concentration
250 nM
Exposure duration
6 h
Method
incubated with
Vehicle
H2O
Methods and source locations

Compound reported in the paper: Echinacoside

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Evaluation of the susceptibility to antibiotics and selected compounds (S66); Results > Echinacoside reduces both auto-aggregation and intracellular c-di-GMP levels of PAO1 in SCFM2 (S156, S157)

aggregates larger than 1000 μm3: aggregates larger than 1000 μm3; comparator: untreated cells — Results > Echinacoside reduces both auto-aggregation and intracellular c-di-GMP levels of PAO1 in SCFM2 (S156, S157)

Echinacoside In Vivo Studies

Male mice received Echinacoside by intraperitoneal injection before OFT. Total distance moved showed no difference between saline and any treatment group. [3]

Locomotor activity in male mice

Animal study · Male C57BL/6 mice; n = 10 per group [3]

Male mice received Echinacoside by intraperitoneal injection before OFT. Total distance moved showed no difference between saline and any treatment group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
total distance movedReported result echinacoside (20, 30 or 40 mg/kg) 30 min before OFT: The total distance moved linked to the animals’ locomotor activity ability showed no difference between saline and all treating groups; p> 0.05.[3]

Conditions shared by the study groups

Route
intraperitoneally injection
Treatment course
30 min before OFT
Vehicle
0.9% saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Echinacoside 20, 30 or 40 mg/kgsalineechinacoside (20, 30 or 40 mg/kg) 30 min before OFT: The total distance moved linked to the animals’ locomotor activity ability showed no difference between saline and all treating groups; p> 0.05.[3]
Echinacoside 20, 30 or 40 mg/kg
Model: Male C57BL/6 mice; n = 10 per group
Methods and source locations

Compound reported in the paper: Echinacoside

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Animals (S1); Materials and methods > Drug administration (S5); Fig. 1 legend (S84, S87, S88)

total distance moved: total distance moved; comparator: saline — Fig. 1 legend (S87, S88)

Echinacoside 20, 30 or 40 mg/kg · Fig. 1 legend (S84, S87, S88)

Specifications

Manufacturer Adooq Bioscience
CAS Number 82854-37-3
Formula C35H46O20
Molecular Weight 786.73
SMILES
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H](O[C@@H]([C@H]2OC(=O)/C=C/C3=CC(=C(C=C3)O)O)CO[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)OCCC5=CC(=C(C=C5)O)O)O)O)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 96 mg/mL (122.02 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Echinacoside Research References

  1. [1] Xie W, Deng L, Lin M, et al. Sirtuin1 Mediates the Protective Effects of Echinacoside against Sepsis-Induced Acute Lung Injury via Regulating the NOX4-Nrf2 Axis. Antioxidants (Basel) (2023). PMID: 38001778 DOI: 10.3390/antiox12111925 Source material
  2. [2] Cai YM, Hong F, De Craemer A, et al. Echinacoside reduces intracellular c-di-GMP levels and potentiates tobramycin activity against Pseudomonas aeruginosa biofilm aggregates. NPJ Biofilms Microbiomes (2025). PMID: 40055321 DOI: 10.1038/s41522-025-00673-2 Source material
  3. [3] Chuang HW, Wang TY, Huang CC, et al. Echinacoside exhibits antidepressant-like effects through AMPAR-Akt/ERK-mTOR pathway stimulation and BDNF expression in mice. Chin Med (2022). PMID: 34983570 DOI: 10.1186/s13020-021-00549-5 Source material

Added to your cart

View Cart Checkout
Loading...